AMENDMENTS TO THE CLAIMS:

This listing of claims will replace all prior versions and listings of claims in the application:

1-24. (Cancelled)

- 25. (Currently Amended) The composition according to claim 18 claim 63, comprising one or more sugars chosen from one or more of glucose, arabinose, mannose, and mannitol.
- 26. (Currently Amended) The composition according to claim 18 claim 63, comprising one or more alcohols chosen from one or both of ethylene glycol and polyethylene glycol.

27.-32. (Cancelled)

- 33. (Previously Presented) A composition comprising a pure form of a proenzyme for the protease activating blood clotting factor VII, optionally further comprising one or more substances chosen from:
 - a) complexing agents of divalent ions;
 - b) amino acids;
 - c) sugars;
 - d) detergents;
 - e) alcohols;
 - f) albumin;
 - g) gelatin;
 - h) fibronectin;
 - i) vitronectin;
 - j) reductants; and
 - k) protease inhibitors;

wherein the amino acid sequence of the protease comprises the following peptide sequences: IYGGFKSTAGKHP (SEQ ID NO:1), LLESLDPDXTPD (SEQ ID NO:2), EFHEQSFRVEKI (SEQ ID NO:3), and SKFTXAXPXQFK (SEQ ID NO:4), wherein X denotes an unidentified amino acid.

- 34. (Previously Presented) The composition according to claim 33, comprising one or more complexing agents of divalent ions chosen from one or more of EDTA, EGTA, and citrate.
- 35. (Previously Presented) The composition according to claim 34, wherein the one or more complexing agents of divalent ions comprises EDTA.
- 36. (Previously Presented) The composition according to claim 34, further comprising one or more substances chosen from amino acids, protease inhibitors, and albumin.
- 37. (Currently Amended) The composition according to claim 36, comprising at least one amino acid comprising arginine and optionally one or more additional amino acids.
- 38. (Currently Amended) The composition according to claim 36, comprising at least one protease inhibitor comprising aprotinin and optionally one or more additional protease inhibitors.
- 39. (Previously Presented) The composition according to claim 33, comprising one or more amino acids chosen from one or more of glutamate, arginine, lysine, and glycine.
- 40. (Previously Presented) The composition according to claim 33, comprising one or more sugars chosen from one or more of glucose, arabinose, mannose, and mannitol.

Application No. 10/674,408 Attorney Docket No. 06478.1446-01

- 41. (Previously Presented) The composition according to claim 33, comprising one or more alcohols chosen from one or both of ethylene glycol and polyethylene glycol.
- 42. (Previously Presented) The composition according to claim 33, comprising one or more reductants chosen from one or more of dithiothreitol, mercaptoethanol, or cysteine.
- 43. (Previously Presented) The composition according to claim 33, comprising one or more protease inhibitors chosen from one or more of aprotinin, α2-antiplasmin,
 C1-esterase inhibitor, inter-α-trypsin inhibitor, and antithrombin III/heparin inhibitor.
- 44. (Previously Presented) The composition according to claim 43, wherein the one or more protease inhibitors comprise aprotinin.
- 45. (Previously Presented) The composition according to claim 43, further comprising one or more amino acids.
- 46. (Previously Presented) The composition according to claim 43, further comprising albumin.
- 47. (Previously Presented) The composition according to claim 33, wherein the composition acts as a biological test reagent.
- 48. (Previously Presented) A composition comprising a mixture of a pure form of the protease activating blood clotting factor VII and a pure form of a proenzyme of said protease, and optionally further comprising one or more substances chosen from:
 - a) complexing agents of divalent ions;

- b) amino acids;
- c) sugars;
- d) detergents;
- e) alcohols;
- f) albumin;
- g) gelatin;
- h) fibronectin;
- i) vitronectin;
- j) reductants; and
- k) protease inhibitors;

wherein the amino acid sequence of the protease comprises the following peptide sequences: IYGGFKSTAGKHP (SEQ ID NO:1), LLESLDPDXTPD (SEQ ID NO:2), EFHEQSFRVEKI (SEQ ID NO:3), and SKFTXAXPXQFK (SEQ ID NO:4), wherein X denotes an unidentified amino acid.

- 49. (Previously Presented) The composition according to claim 48, comprising one or more complexing agents of divalent ions chosen from one or more of EDTA, EGTA, and citrate.
- 50. (Previously Presented) The composition according to claim 49, wherein the one or more complexing agents of divalent ions comprises EDTA.
- 51. (Previously Presented) The composition according to claim 49, further comprising one or more substances chosen from amino acids, protease inhibitors, and albumin.
- 52. (Currently Amended) The composition according to claim 51, comprising at least one amino acid comprising arginine and optionally comprising one or more additional amino acids.

- 53. (Currently Amended) The composition according to claim 51, comprising at least one protease inhibitor comprising aprotinin and optionally comprising one or more additional protease inhibitors.
- 54. (Previously Presented) The composition according to claim 48, comprising one or more amino acids chosen from one or more of glutamate, arginine, lysine, and glycine.
- 55. (Previously Presented) The composition according to claim 48, comprising one or more sugars chosen from one or more of glucose, arabinose, mannose, and mannitol.
- 56. (Previously Presented) The composition according to claim 48, comprising one or more alcohols chosen from one or both of ethylene glycol and polyethylene glycol.
- 57. (Previously Presented) The composition according to claim 48, comprising one or more reductants chosen from one or more of dithiothreitol, mercaptoethanol or cysteine.
- 58. (Previously Presented) The composition according to claim 48, comprising one or more protease inhibitors chosen from one or more of aprotinin, α2-antiplasmin, C1-esterase inhibitor, inter-α-trypsin inhibitor, and antithrombin III/heparin inhibitor.
- 59. (Previously Presented) The composition according to claim 58, wherein the one or more protease inhibitors comprise aprotinin.
- 60. (Previously Presented) The composition according to claim 58, further comprising one or more amino acids.

- 61. (Previously Presented) The composition according to claim 58, further comprising albumin.
- 62. (Previously Presented) The composition according to claim 48, wherein the composition acts as a biological test reagent.
- 63. (New) A composition comprising a pure form of a proenzyme for the protease activating blood clotting factor VII, optionally further comprising one or more substances chosen from:
 - I) complexing agents of divalent ions;
 - m) amino acids;
 - n) sugars;
 - o) detergents;
 - p) alcohols;
 - q) albumin;
 - r) gelatin;
 - s) fibronectin;
 - t) vitronectin;
 - u) reductants; and
 - v) protease inhibitors;

wherein the amino acid sequence of the protease comprises the following peptide sequences: IYGGFKSTAGKHP (SEQ ID NO:1), LLESLDPDXTPD (SEQ ID NO:2), EFHEQSFRVEKI (SEQ ID NO:3), and SKFTXAXPXQFK (SEQ ID NO:4), wherein X denotes an unidentified amino acid.

- 64. (New) The composition according to claim 63, comprising one or more complexing agents of divalent ions chosen from one or more of EDTA, EGTA, and citrate.
- 65. (New) The composition according to claim 64, wherein the one or more complexing agents of divalent ions comprises EDTA.

- 66. (New) The composition according to claim 64, further comprising one or more substances chosen from amino acids, protease inhibitors, and albumin.
- 67. (New) The composition according to claim 66, comprising at least one amino acid comprising arginine and optionally one or more additional amino acids.
- 68. (New) The composition according to claim 66, comprising at least one protease inhibitor comprising aprotinin and optionally one or more additional protease inhibitors.
- 69. (New) The composition according to claim 63, comprising one or more amino acids chosen from one or more of glutamate, arginine, lysine, and glycine.
- 70. (New) The composition according to claim 63, comprising one or more reductants chosen from one or more of dithiothreitol, mercaptoethanol, or cysteine.
- 71. (New) The composition according to claim 63, comprising one or more protease inhibitors chosen from one or more of aprotinin, α2-antiplasmin, C1-esterase inhibitor, inter-α-trypsin inhibitor, and antithrombin III/heparin inhibitor.
- 72. (New) The composition according to claim 71, wherein the one or more protease inhibitors comprise aprotinin.
- 73. (New) The composition according to claim 71, further comprising one or more amino acids.
- 74. (New) The composition according to claim 71, further comprising albumin.
- 75. (New) The composition according to claim 63, wherein the composition acts as a biological test reagent.